Ekso Bionics Holdings Inc
Ekso Bionics Holdings Inc develops and commercializes wearable bionic exoskeletons for medical rehabilitation and industrial applications, generating revenue through product sales and service contracts.
Business. Ekso Bionics Holdings Inc (EKSO.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, generating revenue primarily through product sales. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Ekso Bionics Holdings Inc (EKSO.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, generating revenue primarily through product sales. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.
Ekso Bionics operates with a market capitalization of $42.8 million and a price-to-book ratio of 3.55, indicating a premium valuation relative to its equity base. The company's liquidity position is characterized by a current ratio of 2.42, suggesting moderate short-term solvency, but its operating cash flow of -$6.1 million and free cash flow of -$2.0 million highlight ongoing cash burn. The debt-to-equity ratio of 0.46 reflects a conservative capital structure, with long-term debt of $5.6 million against total equity of $12.1 million.
Profitability metrics reveal significant challenges, with a net loss of $2.4 million and an operating loss of $2.3 million in the latest period. Return on equity of -20.03% and return on assets of -8.95% underscore the company's inability to generate returns for shareholders or asset holders. Gross profit of $2.6 million on $4.95 million in revenue suggests margin pressures, with a gross margin of 53.3%, which is below the industry median for advanced medical equipment firms.
The company's revenue is concentrated in a single business segment focused on exoskeletons for medical and industrial use, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks, particularly in the healthcare and industrial sectors where adoption of bionic technology is still nascent.
Looking ahead, Ekso Bionics is projected to face continued revenue and margin pressures, with no clear path to profitability in the near term. The company's operating cash flow and free cash flow remain negative, and its capital expenditures of -$8,000 suggest minimal investment in growth infrastructure. Analysts have assigned a mean price target of $9.50, which is below the current market price of $12.01, indicating a bearish outlook.
Risk factors include liquidity constraints, with net cash negative after subtracting total debt, and a high probability of continued operating losses. The company's dilution risk is currently low, but its equity base is small, and any future capital raise could significantly dilute existing shareholders. No recent filings or transcripts indicate material changes in strategy or operations.
- Ekso Bionics is valued at a premium to book despite significant operating losses and negative cash flows.
- The company's gross margin of 53.3% is below the industry median for advanced medical equipment firms.
- Revenue is concentrated in a single product line with no geographic diversification.
- Analysts have assigned a bearish price target of $9.50, below the current market price of $12.01.
- Liquidity constraints and negative operating cash flow pose ongoing risks to the company's financial stability.
Bull / Bear case
Generated · model-assistedRevenue grew at a 3.3% CAGR over four years, indicating modest top-line expansion despite recent volatility.
Cash conversion of 2.54 ranks best-in-class among 205 peers, suggesting superior operational efficiency relative to competitors.
Capex to revenue ratio of -0.0016 sits in the top quartile, implying minimal capital intensity requirements.
Long-term debt decreased to $4.1 million in FY2026, reflecting a gradual reduction in leverage obligations.
Gross profit reached $9.5 million in FY2025, demonstrating the ability to generate positive gross margins on sales.
The company carries a high credit risk flag, suggesting significant concerns regarding its ability to meet financial obligations.
Free cash flow remained deeply negative at -$11.0 million in FY2026, highlighting persistent cash burn issues.
In focus — financials by report
Revenue $2.1M, −36,6% YoY; Net income −138,2% YoY.
- ▍Revenue $2.1M, −36,6% YoY
- ▍Net income −138,2% YoY
- ▍Net margin -321.6%
Revenue $3.1M, −38,3% YoY; Operating income −102,2% YoY.
- ▍Revenue $3.1M, −38,3% YoY
- ▍Operating income −102,2% YoY
- ▍Net income −37,0% YoY
- ▍Free cash flow −43,2% YoY
- ▍Net margin -148.9%
Revenue $4.2M, +2,4% YoY; Operating income +46,9% YoY.
- ▍Revenue $4.2M, +2,4% YoY
- ▍Operating income +46,9% YoY
- ▍Net income +31,4% YoY
- ▍Free cash flow +36,3% YoY
- ▍Net margin -33.6%
Revenue $2.1M, −58,4% YoY; Operating income −70,2% YoY.
- ▍Revenue $2.1M, −58,4% YoY
- ▍Operating income −70,2% YoY
- ▍Net income −12,1% YoY
- ▍Free cash flow −17,5% YoY
- ▍Net margin -131.7%
Revenue $3.4M; Operating income -$3.4M.
- ▍Revenue $3.4M
- ▍Operating income -$3.4M
- ▍Net margin -85.7%
Revenue $5.1M; Operating income -$2.2M.
- ▍Revenue $5.1M
- ▍Operating income -$2.2M
- ▍Net margin -67.1%
Revenue $4.1M; Operating income -$2.6M.
- ▍Revenue $4.1M
- ▍Operating income -$2.6M
- ▍Net margin -50.2%
Revenue $5.0M; Operating income -$2.3M.
- ▍Revenue $5.0M
- ▍Operating income -$2.3M
- ▍Net margin -48.8%
Revenue $12.8M, −28,6% YoY; Operating income −26,1% YoY.
- ▍Revenue $12.8M, −28,6% YoY
- ▍Operating income −26,1% YoY
- ▍Net income −3,2% YoY
- ▍Free cash flow −2,6% YoY
- ▍Net margin -91.4%
Revenue $17.9M, −1,9% YoY; Operating income +30,1% YoY.
- ▍Revenue $17.9M, −1,9% YoY
- ▍Operating income +30,1% YoY
- ▍Net income +25,4% YoY
- ▍Free cash flow +26,8% YoY
- ▍Net margin -63.2%
Revenue $18.3M, +41,6% YoY; Operating income +2,9% YoY.
- ▍Revenue $18.3M, +41,6% YoY
- ▍Operating income +2,9% YoY
- ▍Net income −0,8% YoY
- ▍Free cash flow +1,1% YoY
- ▍Net margin -83.1%
Revenue $12.9M, +14,8% YoY; Operating income −22,2% YoY.
- ▍Revenue $12.9M, +14,8% YoY
- ▍Operating income −22,2% YoY
- ▍Net income −54,4% YoY
- ▍Free cash flow −59,7% YoY
- ▍Net margin -116.8%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,41 |
| Revenue | —no estimate | —no estimate | 22,7M USD |
| Operating income | —no estimate | —no estimate | -4,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Ekso Bionics Holdings Inc Market data — financials · 2026-05-27
- Ekso Bionics Holdings Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M